Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma Companies Looking To Consumer Divisions To Feed DTC Efforts

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer plans to use Nicorette OTC marketing experience in developing direct-to-consumer advertising for the prescription smoking cessation drug varenicline, currently under development.

You may also be interested in...



OTC Drug Advertising Outpaces Rx Direct-To-Consumer Spending At J&J, Schering

J&J spent 40% more on OTC ads compared to Rx direct-to-consumer spots during the first nine months. Schering's OTC spending was more than triple expenditures for its prescription consumer advertising due to the Claritin switch.

Judge Orders FDA, Food Safety Group To Set FSMA Implementation Date

FDA’s delays in implementing the Food Safety Modernization Act violated FSMA and the Administrative Procedures Act, a federal court finds in an April 22 order. The agency must meet with plaintiff Center for Food Safety to agree on new implementation deadlines by May 20.

Topics

UsernamePublicRestriction

Register

PS058753

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel